$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next.

SQZ Biotechnologies Co. raised $65 million in a series D round led by new investor Temasek, bringing its total of private capital raised to $167 million. Existing investors GV, Illumina Ventures, Invus, JDRF T1D Fund, NanoDimension and Polaris Partners also participated, along with a new investor in an undisclosed U.S. fund...